CNS Licensing Trends: Volume Falls, Values Rise
According to a new analysis from Datamonitor Healthcare, the volume of deals in the CNS space has fallen since 2012 but the overall value of alliances is increasing, particularly when it comes to up-front payments for potential Alzheimer's therapies.
You may also be interested in...
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.
Regeneron and Teva will partner on the development and commercialization of the late-stage nerve growth factor antibody fasinumab for pain in a deal that will help Regeneron fund a 10,000-patient safety database.
With Scrip still reeling from the news earlier this week that Pfizer and Allergan have called off their $160bn mega-merger, news broke that former darling of the UK biotech scene Heptares, now a wholly-owned subsidiary and the 'R&D engine' of Japanese company Sosei Group Corp., has secured a notable licensing deal with Allergan. Scrip caught up with Heptares CEO Malcolm Weir to get his take on the fall of PfizerGan (PfAllergan?), and of course the small matter of securing a partnership deal worth up to $3.34bn plus potential royalties.